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Abstract
Introduction In LUX-Lung 3 and LUX-Lung 6, afatinib
significantly improved progression-free survival (PFS)
versus chemotherapy in patients with tumors harboring
common epidermal growth factor receptor (EGFR) muta-
tions (Del19/L858R) and significantly improved overall
survival (OS) in patients with tumors harboring Del19
mutations. Patient-reported outcomes stratified by EGFR
mutation type are reported.
Patients and Methods Lung cancer symptoms and health-
related quality of life (QoL) were assessed every 21 days
until progression using the EORTC Quality of Life Core
Questionnaire C30 and its lung cancer-specific module,
LC13. Analyses of cough, dyspnea, and pain were pre-
specified and included analysis of percentage of patients
who improved on therapy, time to deterioration of symp-
toms, and change over time. Global health status (GHS)/
QoL was also assessed. Analyses were conducted for all
patients with tumors harboring Del19 or L858R mutations
and were exploratory.
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Results Compared with chemotherapy, afatinib more
commonly improved symptoms of, delayed time to dete-
rioration for, and was associated with better mean scores
over time for cough and dyspnea in patients with Del19 or
L858R mutations. All three prespecified analyses of pain
showed a trend favoring afatinib over chemotherapy. In
both Del19 and L858R mutations, afatinib was also asso-
ciated with improvements in GHS/QoL. Longitudinal
analyses demonstrated statistically significant improve-
ments in GHS/QoL for afatinib over chemotherapy for
patients with tumors harboring Del19 mutations or L858R
mutations.
Conclusions These exploratory analyses suggest first-line
afatinib improved lung cancer-related symptoms and GHS/
QoL compared with chemotherapy in patients with non-
small-cell lung cancer with tumors harboring common
EGFR mutations, with benefits in both Del19 and L858R
patients. When considered with OS (Del19 patients only)
and PFS benefits, these findings substantiate the value of
using afatinib over chemotherapy in these patient groups.
Key Points for Decision Makers
The benefits of afatinib compared with
chemotherapy, with regard to symptom control of
cough and dyspnea, are observed regardless of
common epidermal growth factor receptor (EGFR)
(Del19 or L858R) mutation type.
Improvements reported in lung cancer-related
symptoms in patients with advanced non-small-cell
lung cancer harboring the Del19 and L858R
mutations add further support to use of afatinib as a
first-choice treatment in these patient populations.
1 Introduction
The first-generation reversible epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors erlotinib and
gefitinib, and the irreversible ErbB family blocker, afatinib,
were all approved as first-line therapy in patients with non-
small-cell lung cancer (NSCLC) harboring EGFR muta-
tions based on results from phase III trials showing
improved progression-free survival (PFS) versus standard
platinum-based chemotherapy [1–3]. Findings from these
and other studies showed that PFS benefit was less pro-
nounced in patients with EGFR exon 21 L858R point
mutations than in patients with exon 19 deletion (Del19)
mutations [2, 4–8]. Data also suggest that Del19 and
L858R mutations might have distinct biological properties
that might affect response to treatment [9, 10].
Differences in overall survival (OS) have not been
reported between erlotinib or gefitinib and chemotherapy,
irrespective of mutation type [8, 11–16]. However, recently
published data have shown differences in OS outcomes
between patients with tumors harboring EGFR Del19
mutations and L858R mutations when treated with afatinib
compared with chemotherapy [17]. OS was substantially
and significantly longer for patients with tumors harboring
Del19 mutations treated with afatinib than for those treated
with chemotherapy in two independent trials; however, OS
was similar in both treatment arms for the L858R mutation
subgroup [17]. There is some uncertainty as to how this
data should be used to guide treatment selection in patients
with NSCLC and if type of common mutation, Del19 or
L858R mutation, should influence treatment choice.
Patient-reported outcomes (PROs) including quality of
life (QoL) are important and clinically relevant endpoints
that can be used to substantiate the clinical benefits of
prolonged PFS and guide treatment choice. Although data
suggests that erlotinib and gefitinib improve QoL com-
pared with chemotherapy in the total population of patients
with EGFR-mutation-positive NSCLC [18–20], data by
mutation type has not been reported for either agent. Here,
we report the analysis of the PROs, by EGFR mutation
type, from two large phase III studies in patients with
EGFR-mutation-positive advanced NSCLC that compared
afatinib with standard of care chemotherapy (LUX-Lung 3
[3] and LUX-Lung 6 [5]). These analyses were exploratory
in nature and designed to investigate whether both types of
common EGFR mutation experience similar improvements
in PROs and discuss the implications of these findings for
daily clinical practice.
2 Methods
2.1 Study Population and Design
The study design, inclusion and exclusion criteria, and
methods of LUX-Lung 3 and LUX-Lung 6, have been
reported in full elsewhere [3, 5]. Both studies were con-
ducted according to the Declaration of Helsinki and Good
Clinical Practice guidelines. In brief, both trials random-
ized eligible patients with stage IIIB/IV lung adenocarci-
noma and confirmed EGFR mutations (Therascreen EGFR
29; Qiagen, Manchester, UK) in a 2:1 fashion to receive
once-daily oral afatinib 40 mg or up to six cycles of
chemotherapy until disease progression, death, or with-
drawal due to adverse events (AEs). Chemotherapy in
LUX-Lung 3 was intravenous cisplatin 75 mg/m2 and
pemetrexed 500 mg/m2 every 21 days, whereas
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chemotherapy in LUX-Lung 6 was intravenous gemc-
itabine 1000 mg/m2 on Day 1 and Day 8 plus cisplatin
75 mg/m2 on Day 1 every 21 days. LUX-Lung 3 was a
global study and LUX-Lung 6 was conducted in China,
South Korea, and Thailand. Treatment randomization was
stratified by EGFR mutation type (Del19 vs L858R vs
other uncommon mutations) in both studies and by ethnic
origin (Asian vs non-Asian) in LUX-Lung 3.
In both studies, PFS, defined as time from randomiza-
tion to progression, determined by independent review, was
the primary endpoint. OS was a key secondary endpoint in
both studies and PROs were an additional secondary
endpoint.
2.2 Patient-Reported Outcomes (PROs)
2.2.1 Assessment
Both the LUX-Lung 3 and LUX-Lung 6 studies included
assessment of lung cancer symptoms and global health
status (GHS)/QoL [21, 22]. Symptoms and GHS/QoL were
assessed using the validated self-administered 30-item
European Organisation for Research and Treatment of
Cancer (EORTC) Quality of Life Core Questionnaire
(QLQ-C30) [23, 24], which includes both multi-item and
single-item measures covering symptoms as well as
adverse events associated with treatment. The 13-question
EORTC lung cancer-specific module QLQ-LC13 [25, 26]
was also used as it was specifically designed for use in
patients with lung cancer undergoing treatment and has
been validated for use in this setting. PROs were assessed
at randomization and every 3 weeks until disease pro-
gression. Further details of these assessments have been
reported in detail previously [21, 22].
Prespecified PRO measures of interest included cough
(assessed by QLQ-LC13 question 1), dyspnea (assessed by
a prespecified composite of QLQ-LC13 questions 3–5),
and pain (assessed by a prespecified composite of QLQ-
C30 questions 9 and 19). These symptoms were selected as
they are established to be key lung cancer symptoms. The
five functional scale scores (physical, role, functional,
cognitive, and social functioning) were also of interest.
Concomitant medications prescribed for cough, dyspnea,
and pain were documented to enable analysis of their
potential impact on reported symptoms.
2.2.2 Statistical Analysis
Analyses were exploratory in nature and neither study was
powered to detect differences in PROs. Data from these
studies are reported together due to the similarity in the trial
designs; data were not pooled as chemotherapy comparator
arms were different. Three analyses were prespecified for
each symptom of interest and included: (i) comparison
between the treatment groups of the percentage of patients
who improved (defined as aC 10-point decrease from
baseline at any time during the trial) compared with those
without improvement (stable or worsened) using a logistic
regression model stratified by race in LUX-Lung 3, without
adjustment for baseline scores; (ii) time to deterioration in
symptoms analysis (measured in months from randomiza-
tion to the first instance of a 10-point worsening in symptom
from baseline)—treatment groups were compared using a
Cox proportional hazards regression model stratified by race
in LUX-Lung 3; and (iii) mean difference in symptom scores
over time (longitudinal analysis) with the assumption that
data are missing at random. For the longitudinal analyses all
data up to the median follow-up time (calculated across all
patients) were included, this was a constant value used across
all analyses. Criteria for clinically meaningful symptom
improvement, as well as details of statistical analysis of these
outcomes, have been reported previously [21, 22]. Func-
tional scale scores were analyzed using longitudinal analysis
only. Updated PRO analyses were completed at the time of
primary OS analysis (January 2014). Analyses were con-
ducted on the prespecified lung cancer symptoms of interest
as well as AE-related symptoms of interest as they are
commonly associated with treatment (nausea, vomiting,
diarrhea, and sore mouth).
Each analysis was conducted for the population of
patients with tumors harboring each of the common EGFR
mutation types (Del19 or L858R), as well as in the total
intention-to-treat population. All analyses were exploratory
and p-values are provided for information only; there were
no adjustments for multiple testing.
3 Results
3.1 Patient Population
Full details of the disposition and the baseline character-
istics of patients in LUX-Lung 3 and LUX-Lung 6 have
been reported previously [3, 5]. Briefly, the majority of
patients were female (afatinib 64% vs chemotherapy 68%),
never smokers (71% vs 76%), had stage IV disease (92%
vs 90%), and had an Eastern Cooperative Oncology Group
performance status of 1 (70% vs 65%). In LUX-Lung 3,
72% of patients were Asian; all patients were Asian in
LUX-Lung 6. In LUX-Lung 3, 88% (n = 203: Del19,
n = 112; L858R, n = 91) of afatinib-treated patients and
90% (n = 104: Del19, n = 57; L858R, n = 47) of
chemotherapy-treated patients had common mutations,
whereas in LUX-Lung 6, 89% (n = 216: Del19, n = 124;
L858R, n = 92) of afatinib-treated patients and 89%
(n = 108: Del 19, n = 62; L858R, n = 46) of
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chemotherapy-treated patients had common mutations
(Fig. 1). Baseline characteristics in patients with Del19 or
L858R mutations were similar to those of the overall
population in both studies. At the time of analysis reported
here, 21 patients in LUX-Lung 3 and 23 patients in LUX-
Lung 6 were still receiving afatinib treatment; no patients
were receiving chemotherapy.
Mean (standard deviation) baseline symptom scores for
cough, dyspnea, pain, and GHS/QoL indicated a low
overall symptom burden for patients in both studies and in
both treatment arms, although symptom burden was
greatest for cough (Table 1). Symptom burden was well
balanced between treatment arms and mutation types.
Compliance rates for EORTC QLQ-C30 questionnaire
completion were high in both trials across treatment arms
and mutation types and were above 90% at all study visits.
Average completion rates over the course of LUX-Lung 3
were 97.1% in Del19 and 96.5% in L858R patients treated
with afatinib and 96.9% in Del19 and 96.1% in L858R
patients treated with chemotherapy. Average completion
rates in LUX-Lung 6 were 97.7% in Del19 and 97.0% in
L858R patients treated with afatinib and 93.9% in Del19
and 93.1% in L858R patients treated with chemotherapy.
3.2 PROs in Patients by Mutation Type
3.2.1 Patients with Lung Cancer Symptom Improvement
The percentages of patients that experienced clinically
meaningful improvements in symptom scores by
mutation type are shown in Fig. 2. In patients with
tumors harboring Del19 mutations, a higher proportion of
afatinib-treated patients experienced clinically meaningful
improvements in dyspnea symptom scores compared
with chemotherapy-treated patients in both studies (LUX-
Lung 3: 69% vs 48%; LUX-Lung 6: 70% vs 43%). In
the Del19 population, the proportion of patients with
improvements in pain was higher for afatinib in LUX-
Lung 3 (60% vs 43%) and the proportion of patients
with improvements in cough washigher for afatinib in
LUX-Lung 6 (75% vs 55%).
For patients with tumors harboring L858R mutations in
LUX-Lung 3, a higher proportion of afatinib-treated
patients experienced clinically meaningful improvements
in dyspnea (64% vs 45%) symptom scores, and a higher
proportion of afatinib-treated patients in LUX-Lung 6
experienced clinically meaningful improvements in cough
(78% vs 58%) and pain (71% vs 34%) symptom scores
compared with chemotherapy-treated patients.
3.2.2 Time to Deterioration of Lung Cancer Symptoms
Afatinib significantly delayed the time to deterioration of
cough and dyspnea, compared with chemotherapy, in
patients with tumors harboring Del19 mutations in both
studies; (Fig. 3 and Supplemental Fig. 1 [see electronic
supplementary material]).
In the group of patients with tumors harboring L858R
mutations, afatinib significantly delayed the time to dete-
rioration of dyspnea in both studies compared with
2179 paents screened
1269 in LUX-Lung 3
910 in LUX-Lung 6
923 had EGFR mutaon conﬁrmed by
central laboratory
452 in LUX-Lung 3
471 in LUX-Lung 6
709 paents randomly assigned to treatment
345 in LUX-Lung 3; 364 in LUX-Lung 6
215 excluded
108 in LUX-Lung 3
107 in LUX-Lung 6
156 sll in study at data cutoﬀ
- 79 in LUX-Lung 3
- 77 in LUX-Lung 6
44 receiving treatment 
- 21 in LUX-Lung 3
- 23 in LUX-Lung 6
112 oﬀ treatment
- 58 in LUX-Lung 3
- 54 in LUX-Lung 6
316 disconnued
- 151 in LUX-Lung 3
- 165 in LUX-Lung 6
62 sll in study at data cutoﬀ; all 
oﬀ treatment
- 30 in LUX-Lung 3
- 32 in LUX-Lung 6
175 disconnued
- 85 in LUX-Lung 3
- 90 in LUX-Lung 6
237 assigned to chemotherapy†472 assigned to afanib
419 common mutaons
- 203 in LUX-Lung 3 (Del19, n=112; L858R, n=91) 
- 216 in LUX-Lung 6 (Del19, n=124; L858R, n=92) 
53 uncommon mutaons
- 27 in LUX-Lung 3
- 26 in LUX-Lung 6
212 common mutaons
- 104 in LUX-Lung 3 (Del19, n=57; L858R, n=47)
- 108 in LUX-Lung 6 (Del 19, n=62; L858R, n=46) 
25 uncommon mutaons
- 11 in LUX-Lung 3
- 14 in LUX-Lung 6
Fig. 1 Study profile.
 Cisplatin-pemetrexed in LUX-
Lung 3; cisplatin-gemcitabine in
LUX-Lung 6. EGFR, epidermal
growth factor receptor
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Table 1 Mean (SD) baseline
symptom scoresa for all
prespecified patient-reported
outcomes symptoms of interest
(cough, dyspnea, and pain) and
GHS/QoL by mutation type
(Del19 and L858R)
Mean (SD) Del19 L858R
Afatinib Chemotherapy Afatinib Chemotherapy
LUX-Lung 3 n = 110 n = 56 n = 90 n = 45
Cough 36.7 (27.2) 33.9 (23.6) 32.6 (24.6) 31.8 (27.8)
Dyspnea 22.1 (18.3) 24.8 (23.8) 21.9 (19.1) 23 (23.7)
Pain 22.6 (23.0) 23.5 (26.2) 28.8 (24.6) 23.1 (25.0)
GHS/QoL 66.4 (19.3) 60 (23.4) 66.0 (20.8) 60.4 (20.2)
Functional scales
Physical 81.2 (19.0) 77.4 (22.2) 80.52 (19.13) 77.27 (20.70)
Role 76.5 (27.0) 72.6 (29.9) 78.28 (26.52) 73.11 (25.72)
Emotional 80.0 (16.8) 73.2 (23.0) 76.97 (18.08) 72.54 (22.70)
Cognitive 87.6 (15.6) 87.5 (17.5) 84.83 (17.52) 81.82 (19.95)
Social 79.8 (22.3) 74.1 (25.2) 78.84 (22.01) 76.14 (27.23)
LUX-Lung 6 n = 124 n = 59 n = 90 n = 43
Cough 36.6 (24.5) 27.5 (23.7) 37.9 (23.4) 32.5 (28.4)
Dyspnea 24 (19.4) 24.2 (19.0) 25.6 (19.1) 24.7 (22.8)
Pain 21.2 (20.0) 24.6 (20.9) 27.5 (23.1) 21.1 (25.3)
GHS/QoL 64.5 (20.7) 65.4 (15.9) 60.1 (21.2) 66.9 (22.6)
Functional scales
Physical 80.2 (20.1) 80.5 (18.4) 77.62 (15.8) 80.5 (18.5)
Role 79.6 (25.4) 79.2 (23.2) 74.90 (23.1) 82.5 (23.0)
Emotional 84.8 (16.3) 80.7 (17.4) 81.13 (18.2) 79.7 (22.5)
Cognitive 89.3 (13.4) 86.8 (15.7) 83.14 (19.6) 86.6 (16.3)
Social 74.4 (23.5) 73.1 (21.8) 73.18 (24.0) 73.2 (25.0)
GHS global health status, QoL quality of life, SD standard deviation
aAll scores range from 0 to 100. For the GHS/QoL scale, a value of 100 was equivalent to the best possible score
and 0 to the worst possible score. For cough, dyspnea, and pain, 100 was equivalent to the highest burden of
symptoms and 0 to the lowest burden. Total patient numbers represent the number of patients with at least one
baseline and one on treatment assessment and, as such, differ slightly from the number of patients randomized to
treatment
p value
LU
X-
Lu
ng
3
Del19 mutation 
Cough 0.51
Dyspnea 0.011
Pain 0.036
L858R mutation 
Cough 0.19
Dyspnea 0.049
Pain 0.25
LU
X-
Lu
ng
6
Del19 mutation 
Cough 0.008
Dyspnea <0.001
Pain 0.5
L858R mutation 
Cough 0.027
Dyspnea 0.07
Pain <0.001
0 10 20 30 40 50 60 70 80 90
Patients (%)
Afatinib Chemotherapy
Fig. 2 Percentages of patients with improvement in all prespecified PROs symptoms of interest: cough, dyspnea, and pain by mutation type
(Del19 and L858R). p-values from logistic regression analysis of ‘improved/not improved’. PRO, patient-reported outcome
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chemotherapy, as well as time to deterioration of pain in
LUX-Lung 6. A trend towards delayed time to deteriora-
tion of pain in LUX-Lung 3, and time to deterioration in
cough, was also observed in patients with tumors harboring
L858R mutations receiving afatinib compared with
chemotherapy.
3.2.3 Longitudinal Analysis of Lung Cancer Symptoms
In patients with tumors harboring Del19 mutations, dif-
ferences in mean symptom scores over time significantly
favored afatinib over chemotherapy for cough and dyspnea
in LUX-Lung 3, and cough, dyspnea, and pain in LUX-
Lung 6 (Fig. 4). For patients with tumors harboring L858R
mutations, differences in mean symptom scores over time
significantly favored afatinib over chemotherapy for cough
and dyspnea in LUX-Lung 3, and cough, dyspnea and pain
in LUX-Lung 6.
3.2.4 Adverse-Event-Related Symptoms
Consistent findings were reported in the time to deterio-
ration analysis in patients with either L858R or Del19
mutations (shorter time to deterioration of nausea and
vomiting with chemotherapy and shorter time to deterio-
ration of diarrhea and sore mouth with afatinib). Longitu-
dinal analyses in patients with tumors harboring either
L858R or Del19 mutations were also consistent (worse
scores for nausea and vomiting with chemotherapy and
worse scores for diarrhea and sore mouth with afatinib).
Time to deterioration and longitudinal analyses of fatigue
were significantly different, favoring afatinib, in patients
with Del19 mutations in both studies and in patients with
L858R mutations in LUX-Lung 6, although were not sig-
nificantly different between treatment groups in patients
with L858R mutations in LUX-Lung 3.
There were no significant differences in the prescription
of concomitant medications for cough, dyspnea, and pain
between treatment arms in LUX-Lung 3. In LUX-Lung 6, a
lower level of concomitant medication use was observed
overall, with greater use of cough (13.6% vs 4.9%) and
pain (46.3% vs 28.7%) medication in the afatinib treatment
arm compared with chemotherapy.
3.2.5 Global Health Status
In longitudinal analysis of LUX-Lung 3 data, patients with
tumors harboring Del19 mutations on afatinib had signifi-
cantly better mean scores over time for GHS/QoL (Fig. 5).
In LUX-Lung 3, no significant difference between treat-
ment arms was observed in the proportion of patients with
improvement or time to deterioration analyses of GHS/
QoL with tumors harboring Del19 mutations.
In patients with tumors harboring Del19 mutations in
LUX-Lung 6, GHS/QoL improvements in afatinib-treated
patients were also observed in all three prespecified
methods of analysis; patients on afatinib had significantly
better mean scores over time [mean treatment difference:
Number of 
patients with
deterioration 
Median time to 
deterioration 
(months)
Afatinib Chemo Afatinib Chemo HR (95% CI) p value
LU
X
-L
un
g
3
Del19 mutation 
Cough 36 23 NE 6.7 0.42 (0.24–0.74) 0.002
Dyspnea 54 33 15.8 3.4 0.61 (0.39–0.95) 0.024
Pain 70 37 4.7 2.7 0.72 (0.48–1.08) 0.10
L858R mutation 
Cough 32 15 NE NE 0.64 (0.34–1.20); 0.16
Dyspnea 45 28 14.5 2.7 0.48 (0.29–0.78) 0.002
Pain 59 29 4.9 3.6 0.78 (0.49–1.22) 0.27
LU
X
-L
un
g
6
Del19 mutation 
Cough 40 22 NE 5.3 0.39 (0.22–0.69) <0.001
Dyspnea 66 36 10.3 2.2 0.48 (0.31–0.74) <0.001
Pain 80 29 4.2 3.8 0.86 (0.55–1.33) 0.49
L858R mutation 
Cough 34 12 17.5 NE 0.51 (0.25–1.05) 0.062
Dyspnea 60 25 5.6 1.6 0.60 (0.37–0.99) 0.038
Pain 53 26 9.7 2.2 0.47 (0.28–0.78) 0.002
HR (95% CI)
Favors afatinib Favors chemotherapy 
 1/8  1/2 2
Fig. 3 Time to deterioration of all prespecified PROs symptoms of
interest: cough, dyspnea, and pain by mutation type (Del19 and
L858R). HRs from Cox proportional hazard model stratified by race
in LUX-Lung 3. p-values calculated from log-rank test. The median
time to deterioration was not evaluable in some groups because there
were not sufficient events at the time of analysis for the median value
to be reached. CI, confidence interval; HR, hazard ratio; NE, not
evaluable; PRO, patient-reported outcome
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- 11.68 (95% CI: - 14.96 to - 8.41); p\0.001; Fig. 5];
afatinib significantly delayed time to deterioration for
GHS/QoL [HR: 0.53 (95% CI: 0.35–0.82); p = 0.003]; and
a significantly greater number of patients had an
improvement in GHS/QoL (63% vs 34%; p\0.001). In
patients with tumors harboring L858R mutations in LUX-
Lung 6, mean scores over time significantly favored afa-
tinib compared with chemotherapy [mean treatment dif-
ference: - 6.53 (95% CI: -10.69 to -2.36); p = 0.002;
Fig. 5] and a significantly higher number of patients treated
with afatinib had an improvement in GHS/QoL (61.2% vs
34.2%; p = 0.007).
3.2.6 Functional Scales
In the longitudinal analysis of data from LUX-Lung 3,
patients with tumors harboring Del19 mutations who
received afatinib had significantly better mean scores over
time for physical, role, and cognitive functioning than
patients treated with chemotherapy (Fig. 5). In LUX-Lung
3, patients on afatinib with tumors harboring L858R
mutations had significantly better mean scores over time
for role and cognitive functioning. In LUX-Lung 6,
patients with tumors harboring common mutations had
significantly better mean scores over time for all functional
scales; results were observed regardless of whether patients
had tumors harboring Del19 mutations or L858R mutations
(Fig. 5).
3.3 PROs in the Intention-to-treat Population
For the intention-to-treat population, the percentage of
patients experiencing clinically meaningful improvements
in symptom scores is shown in Supplemental Fig. 2A, time
to deterioration of symptom scores is shown in Supple-
mental Fig. 2B and differences in mean symptom scores
over time are shown in Supplemental Fig. 2C. Longitudi-
nal analysis of GHS/QoL and functional scale scores are
shown in Supplemental Fig. 2D (see electronic supple-
mentary material). All findings were comparable to the
data reported by mutation type.
4 Discussion
The new analyses described here suggest that the benefits of
afatinib compared with chemotherapy, with regard to symp-
tom control of cough and dyspnea, are observed regardless of
common EGFR (Del19 or L858R) mutation type. In patients
with Del19 or L858R, differences favoring afatinib over
chemotherapy for cough and dyspnea were observed in all
three prespecified analyses, with differences substantially
favoring afatinib over chemotherapy in a number of com-
parisons. All three prespecified analyses of pain generally
showed a trend favoring afatinib over chemotherapy, although
the differences between treatments reached significance in
only a few of the analyses and were sometimes inconclusive.
Number 
of 
patients
Mean treatment 
difference (95% CI) p value
LU
X-
Lu
ng
3
Del19 mutation 
Cough 166 –7.18 (–11.06 to –3.30) <0.001
Dyspnea 166 –7.86 (–11.14 to –4.57) <0.001
Pain 166 0.66 (–3.16 to 4.49) 0.73
L858R mutation 
Cough 135 –5.21 (–9.39 to –1.03) 0.015
Dyspnea 135 –6.44 (–9.69 to –3.19) <0.001
Pain 135 –0.62 (–5.13 to 3.88) 0.79
LU
X-
Lu
ng
6
Del19 mutation 
Cough 183 –6.62 (–10.39 to –2.85) <0.001
Dyspnea 183 –11.41 (–14.26 to –8.57) <0.001
Pain 183 –7.50 (–10.84 to –4.17) <0.001
L858R mutation 
Cough 133 –4.78 (–9.24 to –0.32) 0.036
Dyspnea 133 –6.61 (–10.54 to –2.69) 0.001
Pain 133 –4.70 (–9.37 to –0.03) 0.049
Mean treatment difference  (95% CI)
Favors afatinib Favors chemotherapy 
-18 -16 -14 -12 -10 -8 -6 -4 -2 0 2 4 6
Fig. 4 Longitudinal analysis of all prespecified PROs symptoms of
interest: cough, dyspnea, and pain by mutation type (Del19 and
L858R). Scores range from 0 to 100 (100 is equivalent to the highest
burden of symptoms and 0 to the lowest burden); mean treatment
difference shown as afatinib minus chemotherapy and, as such, a
negative score favors afatinib treatment. CI, confidence interval;
PRO, patient-reported outcome
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Thesenewfindings support previous analyses that have shown
that first-line treatment with afatinib was associated with
better control of cough and dyspnea compared with
chemotherapy and better control of pain in patients with
EGFR-mutation-positive NSCLC [3, 5].
What are the implications of these findings to clinical
practice? Use of afatinib as first-line therapy significantly
prolongs OS and PFS compared with chemotherapy in
patients with advanced NSCLC harboring the Del19
mutation [3, 5]. As such, afatinib should be considered a
first-choice, first-line agent in patients with tumors har-
boring Del19 mutations, with the additional improvements
reported in lung cancer-related symptoms and overall GHS
adding further support to this recommendation.
Treatment guidelines recommend both erlotinib and
gefitinib over chemotherapy as first-line treatment in
patients with EGFR-mutation-positive NSCLC [27, 28].
These recommendations are based on data showing that
both treatments significantly improve PFS
[1, 2, 4, 7, 11, 29, 30] and QoL symptoms [18–20] com-
pared with chemotherapy, as benefits in OS have not been
reported in either the overall study population [8, 11–15] or
by mutation type; specifically, hazard ratios for patients
with L858R mutations, where reported, are greater than
(favoring chemotherapy) [14] or close to 1 [12, 13]. In
agreement with these recommendations, demonstrated
improvements in PFS, combined with improvements in
symptom control, substantiate the value of also recom-
mending afatinib over chemotherapy in patients with
L858R mutations despite the lack of OS benefit [17]. Data
from the LUX-Lung 7 global, randomized, phase IIb trial
comparing first-line afatinib with gefitinib showed that
afatinib significantly improved PFS versus gefitinib in
patients with common EGFR mutations, with efficacy
improvements being observed in both L858R and Del19
mutations [31], and a trend towards improved OS with
afatinib versus gefitinib in both mutation types [32] adding
further support to the use of afatinib in both mutation types.
Number of 
patients Mean treatment difference (95%CI) p-value
LU
X
-L
un
g
3
Del19 mutation 
Global health status
Global health status/QoL 166 −6.59  (−10.01  to −3.18) <0.001
Functional scales
Physical 166 −7.53  (−10.88  to −4.18) <0.001
Role 166 −6.31  (−10.51  to −2.12) 0.003
Emotional 166 −2.22  (−5.35  to  0.9) 0.16
Cognitive 166 −4.6  (−7.66  to −1.53) 0.003
Social 166 −1.97  (−5.64  to  1.69) 0.29
L858R mutation 
Global health status
Global health status/QoL 135 −0.71  (−4.4  to  2.99) 0.71
Functional scales
Physical 135 −3.31  (−7.29  to  0.68) 0.10
Role 135 −4.34  (−8.65  to −0.02) 0.049
Emotional 135 0.4  (−3.04  to  3.85) 0.82
Cognitive 135 −3.93  (−7.57  to −0.28) 0.035
Social 135 0.14  (−4.1  to  4.38) 0.95
LU
X
-L
un
g
6
Del19 mutation 
Global health status
Global health status/QoL 183 −11.68  (−14.96  to −8.41) <0.001
Functional scales
Physical 183 −11.12  (−14.23  to −8.01) <0.001
Role 183 −9.22  (−12.75  to −5.69) <0.001
Emotional 183 −6.93  (−9.76  to −4.09) <0.001
Cognitive 183 −6.22  (−9.16  to −3.28) <0.001
Social 183 −13.98  (−17.77  to −10.19) <0.001
L858R mutation 
Global health status
Global health status/QoL 133 −6.53 (−10.69 to−2.36) 0.002
Functional scales
Physical 133 −8.24 (−12.01 to−4.46) <0.001
Role 133 −7.68 (−12.19 to−3.17) <0.001
Emotional 133 −4.01 (−7.79 to−0.24)
Cognitive 133 −5.86 (−9.7 to−2.01) 0.003
Social 133 −9.21 (−14.07 to−4.35) <0.001
Favors afatinib Favors chemotherapy 
Mean treatment difference  (95% CI)
-18 -16 -14 -12 -10 -8 -6 -4 -2 0 2 4 6 8 10
Fig. 5 Longitudinal analysis of GHS/QoL and functional scale
domains by mutation type (Del19 and L858R). For the GHS/QoL
scale, a value of 100 was equivalent to the best possible score and 0 to
the worst possible score; mean treatment difference shown as
chemotherapy minus afatinib and, as such, a negative score favors
afatinib treatment. CI, confidence interval; GHS, global health status;
QoL, quality of life
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The longitudinal analysis of these parameters provided
statistically significant improvements for afatinib over
chemotherapy in both studies for patients with tumors
harboring Del19 mutations, as well as for patients with
tumors harboring L858R mutations, in LUX-Lung 6. This
suggests that the GHS/QoL of patients with NSCLC with
common EGFR mutations (both for Del19 and L858R)
receiving afatinib is potentially better than with
chemotherapy. These new data also indicate that the
symptoms of diarrhea and sore mouth, as well as other AEs
more commonly observed with afatinib compared with
chemotherapy, did not adversely affect patients’ overall
QoL. Afatinib treatment also showed consistent significant
improvements in scores of all functional scales compared
with chemotherapy in LUX-Lung 6, regardless of common
mutation type, whereas significant differences in functional
scale scores between treatment arms were not as uniformly
seen in the LUX-Lung 3 trial. This likely reflects the dif-
ferential impact of the chemotherapy arms used in each
trial on patient outcome rather than the responsiveness of
the mutation type to improvements in aspects of patient
function with afatinib; the cisplatin/pemetrexed
chemotherapy comparator used in LUX-Lung 3 is gener-
ally considered to have a better tolerability profile than
cisplatin/gemcitabine used in LUX-Lung 6 and, as such, is
likely to have less of an impact on functioning compared
with the LUX-Lung 6 chemotherapy comparator.
The EORTC QLQ-C30 and QLQ-LC13 instruments
used in our analyses have been well validated for the
assessment of PROs and, although LUX-Lung 3 and
LUX-Lung 6 both used comprehensive and prespecified
methods for the assessment of PROs, the analyses repor-
ted here were conducted post hoc and should be consid-
ered to be exploratory. It should be noted that the studies
on which these analyses were based were not powered to
detect significant differences in PRO outcomes and the
number of analyses conducted does increase the chance of
false-positive results being observed (a type I error). The
strengths and limitations of each analysis method should
also be considered: analysis of the percentage of patients
with symptom improvement is of clinical interest yet the
threshold that constitutes a clinically relevant change is
often debated and the presence of asymptomatic patients
at baseline can impact on the results. The event time for
symptom improvement or deterioration could occur at any
stage during the assessment period; time to deterioration
analysis is easy to interpret, yet has limitations associated
with censoring due to progression, and longitudinal
analysis offers comprehensive use of available data, yet is
a complex method of analysis that requires certain
assumptions regarding missing data. However, collec-
tively, the three methods of analysis broaden the per-
spective of the results, thereby enhancing their
interpretation. The overall inferential strategy was to
provide a comprehensive analysis relying on the consis-
tency (and potential inconsistency) of the results to reflect
the strength of the evidence. As such, the general con-
sistency of the results favoring afatinib treatment com-
pared with chemotherapy across studies, mutation groups
(Del19 or L858R), and analysis methods suggests that the
differences observed represent a true treatment effect
rather than a chance occurrence. An additional consider-
ation in interpreting the findings reported here is that
baseline pain scores were low; as such, only a limited
number of patients had a chance to show improvements in
this item. Despite this, a trend towards better control of
pain was observed in both studies.
5 Conclusion
Compared with chemotherapy, first-line treatment with
afatinib generally improves lung cancer-related symp-
toms in patients with EGFR-mutation-positive NSCLC,
with comparable benefits being observed regardless of
common mutation type. Afatinib also results in
improvements in overall QoL and functional improve-
ments compared with chemotherapy, providing further
support for the use of afatinib in the first-line treatment
of this patient group.
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